CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 24 enrolled
Drug / intervention
mirabegrondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04501640
NCT04501640Phase 4Completed
CompareCT.gov

A Phase 4 Open-label, Randomized, Single Oral Dose, Two-way Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of Mirabegron in Healthy Chinese Subjects

Astellas Pharma China, Inc.·interventional·Posted Aug 6, 2020·Updated Nov 12, 2024

In Brief

A Phase 4 clinical trial evaluating mirabegron for Pharmacokinetics of Mirabegron and 2 related conditions. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This study determined the effect of food on the pharmacokinetics (PK) of single oral doses of mirabegron in healthy Chinese male and female participants. This study also evaluated the safety and tolerability of single oral doses of mirabegron in healthy Chinese male and female participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPharmacokinetics of Mirabegron, Food Effect, Healthy Chinese Subjects
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedAug 6, 2020
Enrollment StartSep 21, 2020
Primary CompletionOct 14, 2020
Study CompletionOct 27, 2020
TodayJul 2, 2026
Enrollment to primary: 23 daysPosted 5.9 years ago

Interventions

mirabegrondrug

Oral adminstration